Clinical trial
A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission
NCT04144517 is registered in ClinicalTrials.gov with Mural Oncology, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of ALKS 4230 in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Advanced or Recurrent Head and Neck Squamous Cell Cancer Currently on Treatment With Anti-PD-(L)1 Without Having Achieved a Complete Remission
- Lead sponsor
- Mural Oncology, Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 5, 2020
- Completion date
- January 7, 2022
- Enrollment
- 14 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.